ArticleFrontiers in oncology2024
Alectinib combined with VRCD and BV monoclonal antibody for the treatment of ALK-positive large B-cell lymphoma: a case report and literature review.
Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Anaplastic Lymphoma Kinase (ALK)-Positive Large B-cell Lymphoma in Children: A Case Report and Review of Literature.Cureus · 2026Article
- ALK-positive large B-cell lymphoma presenting in the nasal cavity with CLTC::ALK fusion: a case report of alectinib-integrated therapy followed by autologous hematopoietic stem cell transplantation.Frontiers in oncology · 2026Article
- Alectinib shows promise for the treatment of refractory ALK-positive large B-cell lymphoma: a case report.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a case of a 53-year-old male patient who was diagnosed with anaplastic lymphoma kinase-positive large B-cell lymphoma. A pathological examination showed plasma-cell immunophenotype negative for mature B-lymphocyte markers. The patient received three cycles of an "alectinib + Vincristine + Rituximab + Cyclophosphamide + Doxorubicin (VRCD) " regimen. In the fourth cycle, brentuximab vedotin monoclonal antibody treatment was added to increase the efficacy of the treatment. Positron emission tomography-computed tomography and a bone marrow examination were carried out after four cycles, revealing a complete response. Stem cells were successfully harvested. Thus far, the patient has undergone six treatment cycles and successfully received autologous hematopoietic stem cell transplantation. Currently, the patient is receiving maintenance therapy with alectinib and lenalidomide and remains in a favorable clinical condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.